Fulcrum Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Revenue	2.81	6.34	19.16	8.82	0	0	0
Revenue Growth (YoY)	-55.77%	-66.90%	117.19%	-	-	-	-
Gross Profit	2.81	6.34	19.16	8.82	0	0	0
Selling, General & Admin	41.67	41.69	30.52	21.39	13.15	8.31	4.5
Research & Development	71.8	76.78	69.7	59.04	71.07	25.18	18.49
Other Operating Expenses	0	0.43	0	0	0	0	0
Operating Expenses	113.47	118.9	100.22	80.43	84.22	33.5	22.99
Operating Income	-110.66	-112.56	-81.05	-71.61	-84.22	-33.5	-22.99
Other Expense / Income	-13.33	-2.69	-0.21	-0.79	-1.54	-0.91	-0.03
Pretax Income	-97.34	-109.87	-80.85	-70.82	-82.68	-32.59	-22.96
Net Income	-97.34	-109.87	-80.85	-70.82	-82.68	-32.59	-22.96
Preferred Dividends	0	0	0	0	7.13	6.56	2.41
Net Income Common	-97.34	-109.87	-80.85	-70.82	-89.81	-39.15	-25.37
Shares Outstanding (Basic)	61	45	35	25	11	1	1
Shares Outstanding (Diluted)	61	45	35	25	11	1	1
Shares Change	36.27%	27.23%	39.47%	129.53%	778.76%	76.79%	-
EPS (Basic)	-1.59	-2.44	-2.29	-2.79	-8.13	-31.14	-35.68
EPS (Diluted)	-1.59	-2.44	-2.29	-2.79	-8.13	-31.14	-35.68
Free Cash Flow	-91.47	-99.01	-80.19	-55	-40.34	-31.54	-21.98
Free Cash Flow Per Share	-1.49	-2.20	-2.27	-2.17	-3.65	-25.09	-30.92
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-	-
Operating Margin	-3945.24%	-1774.85%	-422.97%	-811.64%	-	-	-
Profit Margin	-3470.05%	-1732.43%	-421.89%	-802.66%	-	-	-
Free Cash Flow Margin	-3261.07%	-1561.23%	-418.47%	-623.34%	-	-	-
EBITDA	-95.16	-107.46	-78.33	-68.44	-80.62	-31.24	-22.25
EBITDA Margin	-3392.62%	-1694.37%	-408.77%	-775.70%	-	-	-
Depreciation & Amortization	2.17	2.41	2.52	2.38	2.05	1.35	0.72
EBIT	-97.34	-109.87	-80.85	-70.82	-82.68	-32.59	-22.96
EBIT Margin	-3470.05%	-1732.43%	-421.89%	-802.66%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).